Fadi Farhat

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

Joyce O’Shaughnessy, Susana Sousa, Josefina Cruz et al. · European Journal of Cancer · 2021 · 67 citations · Full text

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Yen‐Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy A. Azim et al. · Journal of Clinical Oncology · 2024 · 65 citations · Full text

Desmoplastic small round cell tumors: results of a four-drug chemotherapy regimen in five adult patients

Fadi Farhat, Stéphane Culine, Catherine Lhommé et al. · Cancer · 1996 · 64 citations

FOLFOX-6 Combination as the First-Line Treatment of Locally Advanced and/or Metastatic Pancreatic Cancer

Marwan Ghosn, Fadi Farhat, Joseph Kattan et al. · American Journal of Clinical Oncology · 2007 · 64 citations

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

Philippe Merle, Jean‐Frédéric Blanc, Jean–Marc Phelip et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 58 citations · Full text

Nanoparticles, Nanomedicine, Sorafenib Treatment Failure +12